背景:前列腺癌(PCa)是西方国家男性中最常见的癌症。体外和体内研究表明,氧化应激(OS)和抗氧化剂在包括PCa在内的慢性疾病的发病机理中起着关键作用。这是由于活性氧的产生和抗氧化防御机制受损而促进的。这项研究评估了OS与男性PCa之间的关联。
方法:在Medline上进行了文献检索,PubMed,和ScienceDirect数据库,以及从开始到2015年8月使用关键字“氧化应激”或“活性氧”或“脂质过氧化”和“前列腺癌”进行手动搜索。“包括PCa中OS生物标志物测量数据在内的所有研究都包括在内。
结果:检索了23项病例对照研究,样本量从15到3,613(总共6,439名参与者)。在21项研究中,PCa患者的OS指标明显高于对照组。两个自我对照的案例研究比较了组织活检中PCa细胞和非PCa细胞之间的OS,发现PCa癌细胞中的OS在统计学上较高。抗氧化能力标志物的结果(超氧化物歧化酶,过氧化氢酶,谷胱甘肽,谷胱甘肽还原酶,谷胱甘肽过氧化物酶,尿酸,叶黄素,番茄红素,β-胡萝卜素,维生素A,维生素C,维生素E,和总抗氧化剂)与PCa的关联并不完全一致。
结论:OS谱上调和抗氧化防御系统受损可能在男性PCa患者中发挥作用。为了证实这些发现,使用个性化方法在治疗期间同时监测OS和抗氧化剂标志物的可靠临床试验是必要的.
BACKGROUND: Prostate cancer (PCa) is the most common cancer in men in Western countries. In-vitro and in-vivo studies suggest that oxidative stress (OS) and antioxidants play a key role in the pathogenesis of chronic diseases including PCa, which is promoted by the production of reactive oxygen species and impaired antioxidant defense mechanisms. This study evaluates the association between OS and men with PCa.
METHODS: A literature search was carried out on Medline, PubMed, and ScienceDirect databases, as well as manual searches from inception up to August 2015 using the keywords \"Oxidative stress\" or \"Reactive oxygen species\" or \"Lipid
peroxidation\" AND \"Prostate cancer.\" All studies including data on the measurement of OS biomarkers in PCa were included.
RESULTS: Twenty-three
case control studies were retrieved with sample sizes ranging from 15 to 3,613 (6,439 participants in total). Markers of OS were significantly higher in patients with PCa compared with control groups in 21 studies. Two self-controlled
case studies comparing OS between PCa cells and non-PCa cells in tissue biopsies found OS to be statistically higher in PCa cancer cells. Results on markers of antioxidant capacity (superoxide dismutase, catalase, glutathione, glutathione reductase, glutathione peroxidase, uric acid, lutein, lycopene, beta carotein, vitamin A, vitamin C, vitamin E, and total antioxidants) were not completely consistent in their association with PCa.
CONCLUSIONS: Upregulated OS profiles and impairment of antioxidant defense systems may play a role in men with PCa. To confirm these findings, robust clinical trials utilizing a personalized approach which monitors both OS and antioxidant markers during therapy are warranted.